#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Inclusion body myositis Liposarcoma Neurodermatitis Complex regional pain syndrome Systemic candida Sexually transmitted disease Cholangitis sclerosing Pleomorphic liposarcoma Hypomagnesaemia Retinal dystrophy Chondrosarcoma Selective polysaccharide antibody deficiency Hypophosphatasia Neovascular age-related macular degeneration Retinitis pigmentosa More trials…

    Learn about Rare Diseases

    Focal segmental glomerulosclerosis – Basic Information Rhabdoid tumour Gaucher’s disease type I – Treatment Pituitary-dependent Cushing’s syndrome – Diagnostics Skin angiosarcoma – Diagnostics Mitochondrial myopathy – Life with Disease Pleural mesothelioma malignant – Life with Disease Rhabdomyosarcoma – Life with Disease Hereditary angioedema – Life with Disease Angiosarcoma recurrent – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    IMA401 Entrectinib Norepinephrine Opium, Standardized Powdered Amiloride Hydrochloride Metformin Embonate Ivermectin Vemircopan Fluoroestradiol F-18 Benzocaine Mva-Hbvac Cx-044933 Pomalidomide 64Cu-Dota-Ae105 Bi-1808 Nido-361 Peposertib Dacarbazine Citrate Falbikitug Fludrocortisone More therapies…

    Learn about Your Condition

    Vestibular disorder Vertebrobasilar stroke Bone hypertrophy Skin ulcer Pharyngeal cancer stage II Urea cycle disorder Cardiac failure acute Autism spectrum disorder Anxiety disorder Growth hormone deficiency Basal cell carcinoma Drug use disorder Chronic coronary syndrome Mitral valve prolapse Renal cell carcinoma stage IV More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Orszagos Onkologiai Intezet

Orszagos Onkologiai Intezet

Rath Gyorgy Utca 7-9, Kerulet, Budapest, 1122, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Loncastuximab Tesirine and Rituximab with Standard Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diffuse large B-cell lymphoma
    Investigated Drugs:
    • Dexamethasone
    • Gemcitabine
    • Loncastuximab Tesirine
    Belgium Czechia France Hungary Italy The Netherlands +2

  • Study of Datopotamab Deruxtecan and Durvalumab for Adults with Untreated Triple-Negative or Hormone Receptor-Low/HER2-Negative Breast Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Epirubicin
    • Olaparib
    • Capecitabine
    Austria Belgium Bulgaria France Germany Hungary +3

  • Study Comparing Camizestrant and Palbociclib with Anastrozole and Palbociclib for Patients with ER-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Leuprorelin Acetate
    • Camizestrant
    • Anastrozole
    Austria Belgium Bulgaria Czechia France Germany +7

  • Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

    Not recruiting

    3 1 1
    Investigated Diseases:
    • HER2 positive breast cancer
    Investigated Drugs:
    • Atezolizumab
    • Trastuzumab
    • Trastuzumab Emtansine
    Austria Belgium Bulgaria Czechia Denmark France +8

  • Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Olaparib
    Austria Belgium France Germany Hungary Iceland +6

  • Study on the Safety and Tolerability of Spartalizumab for Patients with Advanced Cancer

    Not recruiting

    1 1 1 1
    Investigated Drugs:
    • 3-[6-(1-Benzylpiperidin-4-Yl)-3-Oxo-1H-Isoindol-2-Yl]Piperidine-2,6-Dione
    • Canakinumab
    • Heterodimeric Interleukin-15
    Belgium Czechia France Germany Hungary Italy +2

  • Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Epcoritamab
    • Cyclophosphamide
    • Doxorubicin Hydrochloride
    Austria Belgium Bulgaria Croatia Czechia Denmark +10

  • Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Follicle centre lymphoma follicular grade I II – III refractory
    Investigated Drugs:
    • Epcoritamab
    • Lenalidomide
    • Rituximab
    Austria Belgium Czechia Denmark France Germany +8

  • Study on Epcoritamab, Rituximab, and Lenalidomide for Adults with Untreated Follicular Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Follicular lymphoma
    • B-cell lymphoma
    Investigated Drugs:
    • Epcoritamab
    • Bendamustine Hydrochloride
    • Cyclophosphamide
    Belgium Bulgaria Croatia Czechia Denmark France +11

  • Study of IO102-IO103 and Pembrolizumab for Patients with Advanced Melanoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Metastatic malignant melanoma
    Investigated Drugs:
    • Io102 Hydrochloride
    • Pembrolizumab
    Belgium Czechia Denmark France Germany Hungary +4
Previous Page
1 … 10 11 12 13 14 … 17
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!